<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Fifty-three asymptomatic patients who, in spite of continuous treatment with <z:chebi fb="10" ids="8776">ranitidine</z:chebi> 300 mg bid for six months, had active severe <z:e sem="disease" ids="C0014868" disease_type="Disease or Syndrome" abbrv="">oesophagitis</z:e>, Savary and Miller grade III-IV or Barretts ulceration at endoscopy were treated with high dose <z:chebi fb="0" ids="4975">famotidine</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>In the severe <z:e sem="disease" ids="C0014868" disease_type="Disease or Syndrome" abbrv="">oesophagitis</z:e> group <z:chebi fb="0" ids="4975">famotidine</z:chebi> 40 mg bid, 13/29 (44%) healed at eight weeks and 17/29 (58%) at sixteen weeks </plain></SENT>
<SENT sid="2" pm="."><plain>In the Barrett's <z:mpath ids='MPATH_579'>ulcer</z:mpath> group <z:chebi fb="0" ids="4975">famotidine</z:chebi> 40 mg tid, 10/24 (41%) healed at eight weeks and 18/24 (75%) at sixteen weeks </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="0" ids="4975">Famotidine</z:chebi> in high doses was well tolerated in this age group (mean 66.75 years), with 5/53 (9%) minor adverse events recorded </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="0" ids="4975">Famotidine</z:chebi> in high dose is effective in the treatment of <z:chebi fb="10" ids="8776">ranitidine</z:chebi> resistant severe <z:e sem="disease" ids="C0014868" disease_type="Disease or Syndrome" abbrv="">oesophagitis</z:e> or Barrett's ulceration </plain></SENT>
</text></document>